Tag: Hospitalizations
-
H3N2 Flu Surge in Waterloo: Early Rise in Cases Raises Alarm
Unfolding Flu Trends in Waterloo The Waterloo region in Ontario is experiencing an earlier-than-usual uptick in influenza activity, accompanied by a rise in hospitalizations. Health officials report that a new variation of the H3N2 flu strain may be contributing to the surge, complicating ongoing seasonal flu patterns. While the flu season typically intensifies later in…
-
Waterloo Region Faces Early Flu Surge as New H3N2 Strain Emerges
Overview: An Unseasonal Rise in Flu Activity Waterloo Region is experiencing an unusually early uptick in influenza activity, with more people seeking medical care and a noticeable increase in hospitalizations. Health officials say a newly identified variation of the H3N2 strain may be contributing to the surge, complicating efforts to predict and manage the season’s…
-
Flu Surge in Waterloo Region: New H3N2 Variant Drives Early Rise in Cases and Hospitalizations
Early Flu Spike in Waterloo Region Linked to New H3N2 Variant Residents of the Waterloo region are contending with an unusually early surge in influenza cases this season. Health officials report a noticeable uptick in hospitalizations, which appears to be driven by a recently identified variation of the H3N2 influenza strain. While influenza activity typically…
-
What’s Behind the ‘Super Flu’ Surge: Symptoms and States Hit Hardest
Rising Flu Activity Across the United States Health officials are sounding the alarm as flu cases surge nationwide. Marketed in some circles as a “super flu,” the current wave has put a heavier burden on specific states while hospital systems in others brace for strain. The latest data from the Centers for Disease Control and…
-
Canada Faces Rising Influenza A Cases: Ontario and Beyond Brace for More Hospital Strain
Overview: A Growing influenza threat across Canada Health officials across Canada are sounding the alarm as influenza activity climbs, with a virulent form of Influenza A driving higher case counts and more hospitalizations. In Ontario, doctors and public health leaders are reporting a noticeable uptick in patients presenting with severe flu symptoms, echoing trends seen…
-
Fluad for 65+ — An Enhanced Adjuvanted Flu Vaccine for Seniors
What Fluad is and who should consider it Fluad is an enhanced trivalent influenza vaccine that contains an adjuvant. In France, the Haute Autorité de Santé (HAS) recommends Fluad for people aged 65 years and older, as a preferential choice for protection against seasonal flu. The HAS considers adjuvanted vaccines like Fluad to be a…
-
Fluad: An Adjuvanted Flu Vaccine for People 65 and Older
Fluad and the Protection of Seniors (65+) Against Influenza Fluad is an enhanced adjuvanted, trivalent influenza vaccine that France’s Haute Autorité de Santé (HAS) recommends preferentially for adults aged 65 and older. In practice, HAS regards adjuvanted vaccines like Fluad as offering protection comparable to high-dose vaccines such as Efluelda, and it positions them as…
-
Dengue vaccine Qdenga reduces hospitalizations during Brazil’s 2024 outbreak
New real-world evidence from Brazil confirms Qdenga’s impact on dengue outcomes The Lancet Infectious Diseases published a pivotal study that marks the first real‑world assessment of Qdenga’s effectiveness after its approval. Conducted amid Brazil’s intense 2024 dengue surge, the observational research focused on adolescents in São Paulo, the epicenter of the outbreak, to understand how…
-
Nirsevimab sharply reduces RSV hospitalizations in U.S. infants during 2024-2025 season
Real-world data show strong protection for U.S. infants As the United States navigates the 2024-2025 RSV season, several U.S. health networks published real-world analyses underscoring the protective effect of nirsevimab in infants. Across multiple settings, infants who received the preventive monoclonal antibody before RSV circulation experienced markedly lower rates of RSV-related hospitalizations compared with comparable…
-
Nirsevimab Slashes RSV Hospitalizations in US Infants During 2024-2025
Real‑world data show strong protection for US infants A recent research letter analyzing the 2024‑2025 RSV season indicates that administering nirsevimab to infants is associated with fewer hospitalizations due to RSV. While randomized trials proved safety and efficacy, real‑world data confirm that protection extends into everyday clinical practice, easing bed occupancy and the caregiving burden…